Timing of high-intensity pulses for myocardial cavitation-enabled therapy
© Miller et al.; licensee BioMed Central Ltd. 2014
Received: 22 April 2014
Accepted: 18 September 2014
Published: 2 October 2014
High-intensity ultrasound pulses intermittently triggered from an ECG signal can interact with circulating contrast agent microbubbles to produce myocardial cavitation microlesions of potential therapeutic value. In this study, the timing of therapy pulses relative to the ECG R wave was investigated to identify the optimal time point for tissue reduction therapy with regard to both the physiological cardiac response and microlesion production.
Rats were anesthetized, prepared for ultrasound, placed in a heated water bath, and treated with 1.5 MHz focused ultrasound pulses targeted to the left ventricular myocardium with an 8 MHz imaging transducer. Initially, the rats were treated for 1 min at each of six different time points in the ECG while monitoring blood pressure responses to assess cardiac functional effects. Next, groups of rats were treated at three different time points: end diastole, end systole, and mid-diastole to assess the impact of timing on microlesion creation. These rats were pretreated with Evans blue injections and were allowed to recover for 1 day until hearts were harvested for scoring of injured cardiomyocytes.
The initial results showed a wide range of cardiac premature complexes in the ECG, which corresponded with blood pressure pulses for ultrasound pulses triggered during diastole. However, the microlesion experiment did not reveal any statistically significant variations in cardiomyocyte injury.
The end of systole (R + RR/3) was identified as an optimal trigger time point which produced identifiable ECG complexes and substantial cardiomyocyte injury but minimal cardiac functional disruption during treatment.
Myocardial contrast echocardiography provides the capability of perfusion imaging with ultrasound [1, 2]. Contrast agents, which consist of suspensions of stabilized microbubbles, are injected intravenously and increase the echogenicity of the myocardium. When relatively high pressure-amplitude ultrasound pulses are used, for example, greater than about 1 MPa at 2 MHz , the microbubbles are destroyed, clearing the contrast enhancement and revealing the relative microbubble content by comparing the before and after images. If the process is repeated with different intervals between the clearance pulses, then the relative perfusion of different regions is discernable. In addition to the diagnostic application, this imaging method can be enhanced for therapeutic purposes. The strong, cavitation-like response of the microbubbles at relatively high peak rarefactional pressure amplitudes (PRPAs) can lead to a variety of microscale bioeffects in contrast-enhanced diagnostic ultrasound . The local bioeffects, or microlesions, are attributable to nucleation of inertial cavitation [5, 6]. The bioeffects have the potential to be harnessed in several therapeutic strategies .
Myocardial contrast echocardiography has been shown to be capable of causing lethal injury of cardiomyocytes, which leads to scattered microlesions throughout the scanned region . The microlesions, which consist of one or a few lethally injured cardiomyocytes, heal within a few weeks with minimal scarring . Recently, this phenomenon was proposed as a means of ultrasound therapy in which the scattered microlesions would innocuously heal, leaving a measured reduction in tissue volume . This noninvasive and relatively gentle method of tissue reduction might be advantageous, for example, in treatment of hypertrophic cardiomyopathy (HCM) and other ventricular hypertrophies. Echocardiography is the optimum method for diagnosis of these conditions, and extension of the imaging methods to therapeutic application may be particularly advantageous clinically. The treatment would be repeatable and avoid methods with relatively high impact and patient risk such as alcohol ablation [11, 12] or surgical myectomy [12, 13]. Parameters for myocardial cavitation-enabled therapy (MCET) were optimized for microlesion production using 1.5-MHz-focused ultrasound pulses, which were trigged at mid-cardiac cycle and guided by 8-MHz diagnostic ultrasound . Evans blue-stained cardiomyocyte scores (SCSs) were used to assess the relative efficacy with 2 or 4 MPa pulses, 1:4 or 1:8 trigger intervals, and 5 or 10 cycle pulses. The results indicated a major increase in efficacy by increasing the PRPA from 2 MPa, in the diagnostic range, to 4 MPa, which often exceeded the microlesioning level needed for therapeutic tissue reduction. The increased intervals and pulse durations did not yield significant increases in the effects. These findings suggested that MCET can potentially become a clinically robust therapeutic tool after refinement and control of the treatment process.
The purpose of this study was to examine the impact of this method on cardiac function during treatment and to determine the best time point in the ECG for application of the therapeutic pulses. We hypothesized that ultrasound-induced arrhythmia, blood pressure perturbation, and microlesion production would have significant dependences on the timing of the therapy pulses within the heart cycle. In addition, for treatment in many patients, significant perturbation of cardiac function might pose significant risks and become an important consideration for treatment planning. An optimum combination of minimal cardiac functional disruption and treatment efficacy is needed for this therapy method. The lethal injury of cardiomyocytes is accompanied by premature complexes (PCs) in the ECG , but the meaning of these complexes was not fully understood. In order to establish whether or not these signals announce actual premature ventricular contractions, or possibly only pulseless electrical activity, the heart function was investigated using real-time blood pressure monitoring for a 4-MPa treatment at six different time points in the cardiac cycle. In addition, to determine if cardiomyocyte microlesion formation is dependent on cardiac cycle and presumed myocardial blood vessel volume (systole = reduced blood volume; diastole = increased volume), treatment efficacy evaluated by microlesion formation was compared with pulses delivered at end diastole, end systole, or mid-diastole. The results provided key information for treatment planning with regard to the response of the heart during treatment and the therapeutic outcome.
Materials and methods
All in vivo animal procedures were conducted with the approval and guidance of the University Committee on Use and Care of Animals. Twenty-eight male Sprague-Dawley rats (Charles River, Wilmington, MA, USA) weighing 331 ± 33 g were tested for this study. One rat was used for preliminary setup and one did not survive for the 1-day examination. Rats are the most common mammalian animal model for cardiovascular research, particularly for studies requiring numerous animals and test groups . Rat models for hypertrophic cardiomyopathy are available , but often difficult to obtain. However, even Sprague-Dawley rats have a tendency toward left ventricular hypertrophy  and therefore seem to be a good model for this study.
Rats were anesthetized by intraperitoneal (IP) injection of a mixture of ketamine (90 mg/kg) and xylazine (9 mg/kg), and the left thorax was shaved and depilated for ultrasound transmission. A 24-gauge cannula was inserted into a tail vein for IV injections of contrast agent. In seven rats, a catheter with a pressure sensor (model SPR-320 2 F catheter, Millar Instruments, Houston, TX, USA) was inserted into a femoral artery and the sensor advanced to the abdominal aorta. The blood pressure signal was amplified with a bridge amplifier and calibrated using a calibration kit (FE221 and MLA1052, ADInstuments, Inc., Colorado Springs, Co, USA). In 21 rats, Evans blue dye in saline (20 mg/ml) was injected IV at a dose of 100 mg/kg as a vital stain for cardiomyocytes . ECG electrodes were applied and the rats were positioned in a warmed water bath for ultrasound scanning and treatment. The ECG and blood pressure signals were digitized (Powerlab 4/30, ADInstruments Inc., Colorado Springs, CO, USA), recorded, and analyzed with the aid of software (Chart Pro 5, v. 5.5.5, ADInstruments Inc., Colorado Springs, CO, USA).
Ultrasound exposure was provided by a laboratory system with guidance by diagnostic ultrasound imaging. The 1.9-cm-diameter therapy transducer with a 3.8-cm focus was mounted on a moveable gantry together with the 8-MHz diagnostic probe used at 8 MHz, 5-cm depth, and low -14-dB power setting (mechanical index 0.2). The setup provided targeting of the therapy beam and for low-power imaging of the heart during exposure. The aim was adjusted to focus the beam into the window between ribs and between the sternum and lung and to enter the heart approximately at the middle of the left ventricle. The exposure consisted of bursts of eight pulses triggered from the ECG signal using optimal parameters of five cycle pulses with 4-MPa PRPA, determined previously . For this study, the pulse amplitudes were re-measured in the water bath using a calibrated hydrophone (Model 805, Sonora Medical systems Inc., Longmont, Co, USA). The pulses were triggered 1:4 at a desired time point relative to the heart cycle determined by the ECG signal.
The ECG signal and the blood pressure signal, when monitored, were recorded for 1 min before treatment, during treatment, and for 1 min after treatment. The ECG signal provides a crude monitor of the treatment because premature complexes in the ECG at the trigger points are strongly correlated with lethal cardiomyocyte injury. For rats with overnight recovery, the ECG also was recorded for 1 min prior to euthanasia. Definity® (Lantheus Medical Imaging, Inc., North Billerica, MA, USA) ultrasound contrast agent was infused at 5 μl/kg/min, diluted 100:1 in sterile saline. After placement and stabilization of a rat in the water bath for a few minutes, the R wave-to-R wave (RR) interval was measured and the desired trigger point set. For exposure, the probes were set, the Definity infusion was initiated, and the therapy exposure was started at the appearance of the contrast agent in the left ventricle.
The development of microlesions was assessed in samples obtained 1 day after treatment. The microlesions were scored on the basis of Evans blue staining . Each heart was evaluated from up to 40 frozen sections cut at 200-μm spacing, and the scores were totaled in an effort to characterize the overall impact. For these therapy experiments, the large accumulations of stained cells in frozen sections were often difficult to accurately count and the resulting scores remained qualitative (rather than an actual cell count). As an additional measure of the overall cardiomyocyte injury, plasma samples were collected after 1 day and analyzed for troponin I with an ELISA assay kit (Rat Cardiac Tn-I (Ultra Sensitive), Life Diagnostics Inc., West Chester, PA, USA). This cardiac enzyme is a sensitive indicator of cardiac injury in rodents  and provides an indicator of the total amount of cell killing.
The study was conducted in two parts. The first part tested six rats using varying trigger timing with blood pressure monitoring. The RR interval of each rat was determined, and the trigger time point was stepped by increments of RR/6 for six 1-min treatments. In order to average any trend with time for the six treatments, the sequence was started at a different time point for each rat. Specifically, the first through sixth rat was started at the R wave (R + 0RR/6), the R wave plus a delay of RR/6 (R + RR/6), R + 2RR/6, R + 3RR/6, R + 4RR/6, and R + 5RR/6, respectively. Rats in part 1 had the ECG and blood pressure signals evaluated and samples of the treated area of the heart taken for histology approximately 15 min after the conclusion of treatments. The second part of the study involved 20 rats in four groups treated as shams or treated with pulse triggering at end diastole (R wave), at end systole (R + 2RR/6), or at mid-diastole (R + 4RR/6). These rats had Evans blue injection and evaluation of the microlesion production in hearts sampled the next day.
Results are reported as the means plus or minus one standard deviation or plotted with standard error bars. The data were evaluated by statistical analysis software (SigmaPlot for Windows v. 11.0, Systat Software Inc., San Jose, CA, USA). Student’s t-tests were used to compare means of the measured parameters, with statistical significance assumed at P < 0.05. In addition, repeated-measures ANOVA analysis was used to examine the significance of results for part 1, in which each rat had all six test conditions.
Part 1 results
Part 2 results
The timing of the therapy pulses relative to the R wave can be readily varied for MCET. In this study, the influence of the trigger time point was investigated with regard to both the physiological cardiac response and the microlesion production. In the first part of the study, rats were treated for 1 min at each of six different time points in the ECG with blood pressure monitoring during treatment. This experiment revealed large differences in the functional response of the heart in terms of the ECG and blood pressure signals for different trigger time points. To evaluate the impact of the ultrasound treatment on cardiomyocyte injury, three different time points were investigated: the R wave (end diastole), R wave plus one third of the R-to-R interval (2RR/6, end systole), and R wave plus 4RR/6 (mid-diastole). The results showed no significant differences in the stained cell scores or plasma troponin measurements for these three trigger time points.
The ECG signal showed many premature complexes for trigger points other than at the R wave, see Figure 2. The blood pressure trace helped to identify key timing reference points, such as the closing of the aortic valve at end of systole, which occurred at about R + 2RR/6. The time points correspond to events in the heart cycle, which is shown in a Wiggers diagram . For triggers at the R wave, there was essentially no perturbation in heart function shown by the ECG or blood pressure signals. For R + 1RR/6 and R + 2RR/6, PCs were observed but no blood pressure pulse was generated, because the heart was already in contraction with the aortic valve open. However, the blood pressure signal revealed premature pulses generated after PCs for triggering during diastole at R + 3RR/6, R + 4RR/6, and R + 5RR/6, as shown in Figure 1. These blood pulses must have required the mitral valve to re-close and the aortic valve to re-open. The compensatory pauses resulted in significant decreases in diastolic blood pressure of up to 15% at the end of diastole (Figure 3). The trigger timing at R + 5RR/6 produced minimal disturbance of the heart cycle but must have interacted with the atrial contraction occurring with the P-wave.
The optimum trigger time point appears to be at end of systole (R + 2RR/6). This setting yields clearly identifiable PCs, which are an indicator of microlesion production  and provide real-time feedback on treatment efficacy. The hypothesis that treatments occurring at end systole might be less effective, because of decreased myocardial vessel blood volume, was not supported (see Figures 6 and 7). Although this timing results in a prolonged compensatory pause, which reduces end-diastolic blood pressure for that cycle and may be felt by patients who are awake, the PCs appear to be pulseless electrical signals. If the trigger timing is set in diastole, then a pulse is generated by premature ventricular contractions and stressful valve actuation might occur. This finding further refines MCET procedures, which also may be applicable to other cardiac therapy methods, such as drug, gene, or stem cell delivery. Further research for development of better microlesion scoring is in progress . In addition, improved real-time monitoring to control and define the actual tissue reduction created will be needed for safe and effective therapeutic application.
MCET allows the opportunity to adjust the timing of therapy pulse-bursts within the cardiac cycle. The end of systole (R + RR/3) was identified as an optimal trigger time point which produced identifiable ECG complexes and substantial cardiomyocyte injury but minimal cardiac functional disruption during treatment.
This work was supported by PHS grant HL114595 awarded by the National Institutes of Health, DHHS.
- Dijkmans PA, Senior R, Becher H, Porter TR, Wei K, Visser CA, Kamp O: Myocardial contrast echocardiography evolving as a clinically feasible technique for accurate, rapid, and safe assessment of myocardial perfusion: the evidence so far. J Am Coll Cardiol. 2006, 48: 2168-77. 10.1016/j.jacc.2006.05.079.View ArticlePubMedGoogle Scholar
- Porter TR, Xie F: Myocardial perfusion imaging with contrast ultrasound. JACC Cardiovasc Imaging. 2010, 3: 176-87. 10.1016/j.jcmg.2009.09.024.View ArticlePubMedGoogle Scholar
- Wei K, Jayaweera AR, Firoozan S, Linka A, Skyba DM, Kaul S: Quantification of myocardial blood flow with ultrasound-induced destruction of microbubbles administered as a constant venous infusion. Circulation. 1998, 97: 473-83. 10.1161/01.CIR.97.5.473.View ArticlePubMedGoogle Scholar
- Miller DL, Averkiou MA, Brayman AA, Everbach EC, Holland CK, Wible JH, Wu J: Bioeffects considerations for diagnostic ultrasound contrast agents. J Ultrasound Med. 2008, 27: 611-32.PubMedGoogle Scholar
- Rota C, Raeman CH, Child SZ, Dalecki D: Detection of acoustic cavitation in the heart with microbubble contrast agents in vivo: a mechanism for ultrasound-induced arrhythmias. J Acoust Soc Am. 2006, 120: 2958-64. 10.1121/1.2346132.View ArticlePubMedGoogle Scholar
- Miller DL: Overview of experimental studies of biological effects of medical ultrasound caused by gas body activation and inertial cavitation. Prog Biophys Mol Biol. 2007, 93: 314-30. 10.1016/j.pbiomolbio.2006.07.027.View ArticlePubMedGoogle Scholar
- Laing ST, McPherson DD: Cardiovascular therapeutic uses of targeted ultrasound contrast agents. Cardiovasc Res. 2009, 83: 626-35. 10.1093/cvr/cvp192.PubMed CentralView ArticlePubMedGoogle Scholar
- Miller DL, Li P, Dou C, Gordon D, Edwards CA, Armstrong WF: Influence of contrast agent dose and ultrasound exposure on cardiomyocyte injury induced by myocardial contrast echocardiography in rats. Radiology. 2005, 237: 137-43. 10.1148/radiol.2371041467.View ArticlePubMedGoogle Scholar
- Miller DL, Li P, Gordon D, Armstrong WF: Histological characterization of microlesions induced by myocardial contrast echocardiography. Echocardiography. 2005, 22: 25-34. 10.1111/j.0742-2822.2005.03184.x.View ArticlePubMedGoogle Scholar
- Miller DL, Dou C, Owens GE, Kripfgans OD: Optimization of ultrasound parameters of myocardial cavitation microlesions for therapeutic applications. Ultrasound Med Biol. 2014, 40: 1228-36. 10.1016/j.ultrasmedbio.2014.01.001.PubMed CentralView ArticlePubMedGoogle Scholar
- Leonardi RA, Kransdorf EP, Simel DL, Wang A: Meta-analyses of septal reduction therapies for obstructive hypertrophic cardiomyopathy: comparative rates of overall mortality and sudden cardiac death after treatment. Circ Cardiovasc Interv. 2010, 3: 97-104. 10.1161/CIRCINTERVENTIONS.109.916676.View ArticlePubMedGoogle Scholar
- Marian AJ: Contemporary treatment of hypertrophic cardiomyopathy. Tex Heart Inst J. 2009, 36: 194-204.PubMed CentralPubMedGoogle Scholar
- Maron BJ, McKenna WJ, Danielson GK, Kappenberger LJ, Kuhn HJ, Seidman CE, Shah PM, Spencer WH, Spirito P, Ten Cate FJ, Wigle ED, Task Force on Clinical Expert Consensus Documents. American College of Cardiology; Committee for Practice Guidelines. European Society of Cardiology: American College of Cardiology/European Society of Cardiology clinical expert consensus document on hypertrophic cardiomyopathy. A report of the American College of Cardiology Foundation Task Force on Clinical Expert Consensus Documents and the European Society of Cardiology Committee for Practice Guidelines. J Am Coll Cardiol. 2003, 42: 1687-713. 10.1016/S0735-1097(03)00941-0.View ArticlePubMedGoogle Scholar
- Miller DL, Dou C, Lucchesi BR: Are ECG premature complexes induced by ultrasonic cavitation electro-physiological responses to irreversible cardiomyocyte injury?. Ultrasound Med Biol. 2011, 37: 312-20. 10.1016/j.ultrasmedbio.2010.11.012.PubMed CentralView ArticlePubMedGoogle Scholar
- Bader M: Rat models of cardiovascular disease Ch 27. Methods Mol Biol. 2010, 597: 403-14. 10.1007/978-1-60327-389-3_27.View ArticlePubMedGoogle Scholar
- de Resende MM, Kriegel AJ, Greene AS: Combined effects of low-dose spironolactone and captopril therapy in a rat model of genetic hypertrophic cardiomyopathy. J Cardiovasc Pharmacol. 2006, 48: 265-73. 10.1097/01.fjc.0000248236.43760.86.View ArticlePubMedGoogle Scholar
- McAdams RM, McPherson RJ, Dabestani NM, Gleason CA, Juul SE: Left ventricular hypertrophy is prevalent in Sprague-Dawley rats. Comp Med. 2010, 60: 357-63.PubMed CentralPubMedGoogle Scholar
- O’Brien PJ, Smith DE, Knechtel TJ, Marchak MA, Pruimboom-Brees I, Brees DJ, Spratt DP, Archer FJ, Butler P, Potter AN, Provost JP, Richard J, Snyder PA, Reagan WJ: Cardiac troponin I is a sensitive, specific biomarker of cardiac injury in laboratory animals. Lab Anim. 2006, 40: 153-71. 10.1258/002367706776319042.View ArticlePubMedGoogle Scholar
- Stoelting RK, Hillier SC: Heart. Pharmacology and Physiology in Anesthetic Practice. 2006, Philadelphia: Lippincott Williams & Wilkins, 749-60. 4Google Scholar
- Zhu YI, Miller DL, Dou C, Kripfgans OD: 14th International Symposium on Therapeutic Ultrasound. 2014, Abstract April 5, 11:00 AMGoogle Scholar
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.